Edition:
United States

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

68.67EUR
3:36am EST
Change (% chg)

€0.30 (+0.44%)
Prev Close
€68.37
Open
€68.80
Day's High
€68.90
Day's Low
€68.40
Volume
130,152
Avg. Vol
1,070,721
52-wk High
€73.55
52-wk Low
€52.39

FREG.DE

Chart for FREG.DE

About

Fresenius SE & Co KGaA is a health care company. It operates in the healthcare sector and offers products and services for dialysis, hospitals and outpatient medical care. It focuses on the hospital operations and offers engineering and services for hospitals and other health care facilities. The Company’s operating segments... (more)

Overall

Beta: 0.54
Market Cap(Mil.): €37,396.48
Shares Outstanding(Mil.): 546.97
Dividend: 0.55
Yield (%): 0.80

Financials

  FREG.DE Industry Sector
P/E (TTM): 25.31 38.30 30.37
EPS (TTM): 2.70 -- --
ROI: 8.96 8.89 15.17
ROE: 13.62 12.43 16.51

BRIEF-Fresenius sees further growth prospect for Kabi unit

* CEO says still sees opportunities for Kabi to grow, both organically and via M&A

Oct 27 2016

Fresenius wins injunction barring generic thyroid hormone injection

A federal judge has barred generic drug maker Fera Pharmaceuticals LLC from selling a generic version of Fresenius Kabi's injectable thyroid hormone levothyroxine, finding that Fresenius was likely to win a patent lawsuit against Fera.

Sep 22 2016

Fitch: Fresenius' Quironsalud Buy Adds Scale, Diversification; No Rating Impact

(The following statement was released by the rating agency) LONDON, September 06 (Fitch) Fitch Ratings says German healthcare group Fresenius SE & Co KGaA's (FSE; BBB-/Stable, including Fresenius Medical Care AG & Co. KGaA (FMC), together Fresenius) acquisition of Spain-based private hospital group Quironsalud for an estimated EUR5.76bn, will have no impact on its existing ratings. Despite being predominantly debt-funded, the transaction will use headroom available under the current rating,

Sep 06 2016

UPDATE 2-Germany's Fresenius takes expansion plans to new heights with $6.4 bln Spanish healthcare acquisition

* Price includes assumed debt, buys from CVC, senior managers

Sep 06 2016

REFILE-European shares hover near 3-mo highs, Ingenico slumps

LONDON, Sept 6 European shares rose slightly on Tuesday and held near their highest levels since April supported on the day by the energy sector and a jump in shares of healthcare firm Fresenius which rose following an acquisition in Spain.

Sep 06 2016

Fresenius buys Spanish hospital chain for 5.76 bln eur

FRANKFURT, Sept 5 German healthcare group Fresenius agreed to take over Spain's biggest private hospital chain, Quironsalud, for 5.76 billion euros ($6.42 billion), cementing its position as Europe's largest private-sector hospital operator.

Sep 05 2016

Lonza buys InterHealth in health push

ZURICH Swiss specialty chemicals and pharmaceutical ingredients company Lonza has announced a deal worth up to $300 million to buy InterHealth Nutraceuticals, a developer and manufacturer of nutritional ingredients used in dietary supplements.

Aug 15 2016

New Fresenius CEO says is 'very ready' for deals

FRANKFURT The new boss of Fresenius, who in his previous job as head of finance worked on several takeover deals for the diversified German healthcare group, said large transactions might well remain his hallmark.

Aug 02 2016

New Fresenius CEO says is "very ready" for deals

FRANKFURT, Aug 2 The new boss of Fresenius , who in his previous job as head of finance worked on several takeover deals for the diversified German healthcare group, said large transactions might well remain his hallmark.

Aug 02 2016

Fitch Upgrades Fresenius to 'BBB-'; Outlook Stable

(The following statement was released by the rating agency) FRANKFURT/BARCELONA/LONDON, July 29 (Fitch) Fitch Ratings has upgraded Fresenius Medical Care AG & Co. KGaA's (FMC) and Fresenius SE & Co. KGaA's (FSE; together Fresenius) Long-Term Issuer Default Ratings to 'BBB-' from 'BB+'. The Outlooks are Stable. Fitch has also upgraded the Short-Term IDR to 'F3' from 'B'. A full list of rating actions is below. The upgrade reflects Fresenius' improving business risk profile, driven by its inc

Jul 29 2016

Earnings vs. Estimates